Gastrointestinal cancers
Cancer types for which bacterial immunotherapy has been tested extensively in Asia include gastrointestinal cancers.
As an example an overview of literature on gastric cancer is provided below:
- Tanaka, N., Gouchi, A., Ohara, T., Mannami, T., Konaga, E., Fuchimoto, S., Okamura, S., Sato, K. and Orita, K. (1994), Intratumoral injection of a streptococcal preparation, OK-432, before surgery for gastric cancer. A randomized trial. Cancer, 74: 3097-3103.
- Gochi, A., Orita, K., Fuchimoto, S. et al. The prognostic advantage of preoperative intratumoral injection of OK-432 for gastric cancer patients. Br J Cancer 84, 443-451 (2001).
- Tsujitani S, Okamura T, Baba H, Korenaga D, Haraguchi M, Sugimachi K. Endoscopic intratumoral injection of OK-432 and Langerhans' cells in patients with gastric carcinoma. Cancer. 1988 May 1;61(9):1749-53.
- Satomi T, Inoue S, Fujita T, Ogawa S, Honda H, Hayashi M. [Effect of endoscopical administration of OK-432 in 4 patients with advanced esophageal or gastric cancer]. Gan No Rinsho. 1989 Mar;35(4):512-5. Japanese. PMID: 2541269.
- Nakazawa S, Yoshino J, Kijima Y, Yasumasa N, Ohhashi S, Mizutani K. The endoscopic intratumor administration of OK-432 in gastric cancer unsuitable for surgery. Endoscopy. 1989 Jul;21(4):168-71.
- Yamaguchi Y, Satoh Y, Miyahara E, Noma K, Funakoshi M, Takashima I, Sawamura A, Toge T. Locoregional immunotherapy of malignant ascites by intraperitoneal administration of OK-432 plus IL-2 in gastric cancer patients. Anticancer Res. 1995 Sep-Oct;15(5B):2201-6. PMID: 8572625.
- Tanaka H, Muguruma K, Ohira M, Kubo N, Yamashita Y, Maeda K, Sawada T, Hirakawa K. Impact of adjuvant immunochemotherapy using protein-bound polysaccharide-K on overall survival of patients with gastric cancer. Anticancer Res. 2012 Aug;32(8):3427-33. PMID: 22843926.
- Takeda T, Wakasugi T, Katsumoto Y, Sakita I, Nagaoka H, Morimoto H, Tsujinaka T, Monden T, Shiozaki H, Shimano T, et al. [Effect of intratumoral injection of the mixture of OK-432 and fibrinogen (OK/fbg) on gastric cancer]. Gan To Kagaku Ryoho. 1992 Aug;19(10 Suppl):1458-60. Japanese. PMID: 1530293.
- Monden T, Morimoto H, Murotani M, Yagyu T, Nagaoka H, Shimano T, Mori T. [Intratumoral injection of OK-432 in conjunction with fibrinogen greatly enhances antitumor effect on colorectal carcinomas]. Nihon Geka Gakkai Zasshi. 1991 Jan;92(1):31-6. Japanese. PMID: 1707498.
- Nio Y, Ohgaki K, Tsuchitani T, Imai S, Shiraishi T, Tobe T. Orally administered streptococcal preparation, OK-432 augments the antitumor immunity of patients with gastric or colorectal cancer. Biotherapy. 1990;2(3):213-22. doi: 10.1007/BF02173522. PMID: 2206774.
- Shiraishi T, Nio Y, Imai S, Tsubono M, Morimoto H, Tseng CC, Tobe T, Tanaka T, Kitamura O, Sakanashi S, et al. [A double blind study of the evaluation of the optimal dose and its frequency in oral administration of OK-432 (Picibanil) by immunological parameters (the 1st report)]. Nihon Gan Chiryo Gakkai Shi. 1990 Apr 20;25(4):799-811. Japanese. PMID: 2196311.
- Yoshikawa T, Saito M, Tsuburaya A, Kobayashi O, Sairenji M, Motohashi H, Yanoma S, Ono Y. [Distribution of lymphocytes to tumor tissue and regional lymph nodes in patients with gastric cancer--the effects of oral administration of OK-432]. Gan To Kagaku Ryoho. 1999 Oct;26(12):1813-6. Japanese. PMID: 10560401.
- Kim SY, Park HC, Yoon C, Yoon HJ, Choi YM, Cho KS. OK-432 and 5-fluorouracil, doxorubicin, and mitomycin C (FAM-P) versus FAM chemotherapy in patients with curatively resected gastric carcinoma: a randomized Phase III trial. Cancer. 1998 Nov 15;83(10):2054-9.
- Kim JP, Kwon OJ, Oh ST, Yang HK. Results of surgery on 6589 gastric cancer patients and immunochemosurgery as the best treatment of advanced gastric cancer. Ann Surg. 1992 Sep;216(3):269-78; discussion 278-9. doi: 10.1097/00000658-199209000-00006. PMID: 1417176; PMCID: PMC1242606.
- Arinaga S, Karimine N, Takamuku K, Nanbara S, Inoue H, Abe R, Watanabe D, Matsuoka H, Ueo H, Akiyoshi T. A trial of adjuvant chemoimmunotherapy with mitomycin C and OK-432 for stage III gastric carcinoma. J Surg Oncol. 1992 Jul;50(3):187-9. doi: 10.1002/jso.2930500312. PMID: 1619943.
- Yasuyuki ASADA, Katsuya MORITA, Syouji MIURA, Yoshinori MUNEMOTO, Yoshio KASAHARA, Hideo SAITO, Takeshi MITSUI, Yoshiro IIDA, Masakiyo FUJISAWA, RESULTS OF IMMUNOCHEMOSURGERY WITH OK-432 IN ADVANCED GASTRIC CANCER, The journal of the Japanese Practical Surgeon Society, 1996, Volume 57, Issue 3, Pages 509-516, Released on J-STAGE February 10, 2009
- Oshihiko Maehara, Toshiro Okuyama, Yoshirio Kakeji, Hideo Baba, Motonosuke Furusawa, Keizo Sugimachi, Postoperative immunochemotherapy including streptococcal lysate OK-432 is effective for patients with gastric cancer and serosal invasion,The American Journal of Surgery,Volume 168, Issue 1,1994,Pages 36-40,ISSN 0002-9610,
- Kobayashi G. [Augmentation of cytotoxicity of regional lymph node lymphocytes of gastric cancer after intratumoral injection of OK-432]. Nihon Geka Gakkai Zasshi. 1990 Jan;91(1):68-76. Japanese. PMID: 2314383
- Obi Y. [Analysis of immunological response of regional lymph node lymphocytes from patients with gastric cancer after endoscopic local injection of biological response modifier (BRM)]. Nihon Geka Gakkai Zasshi. 1991 Mar;92(3):293-302. Japanese. PMID: 2051981.
- Yoshikawa T, Tsuburaya A, Kobayashi O, Sairenji M, Motohashi H, Noguchi Y. A combination immunochemotherapy of 5-fluorouracil, cisplatin, leucovorin, and OK-432 for advanced and recurrent gastric carcinoma. Hepatogastroenterology. 2003 Nov-Dec;50(54):2259-63. PMID: 14696512.
- Sakamoto J, Teramukai S, Nakazato H, Sato Y, Uchino J, Taguchi T, Ryoma Y, Ohashi Y. Efficacy of adjuvant immunochemotherapy with OK-432 for patients with curatively resected gastric cancer: a meta-analysis of centrally randomized controlled clinical trials. J Immunother. 2002 Sep-Oct;25(5):405-12. doi: 10.1097/00002371-200209000-00004. PMID: 12218778.
- Shiraishi T, Nio Y, Imai S, Tsubono M, Morimoto H, Tseng CC, Tobe T, Tanaka T, Kitamura O, Sakanashi S, et al. [A double blind study to evaluate the optimal dose and its frequency for oral administration of OK-432 (picibanil) by immunological parameters (the 2nd report)]. Nihon Gan Chiryo Gakkai Shi. 1990 May 20;25(5):997-1012. Japanese. PMID: 2202770.
- Nio Y, Tobe T. [Immunity of gut-associated lymphoid tissue and the role of the oral immunotherapy in multi-disciplinary treatment of the digestive organ cancer]. Nihon Geka Gakkai Zasshi. 1989 Sep;90(9):1436-8. Japanese. PMID: 2586435.
- A comprehensive multi-institutional study on postoperative adjuvant immunotherapy with oral streptococcal preparation OK-432 for patients after gastric cancer surgery. Kyoto Research Group for Digestive Organ Surgery. Ann Surg. 1992 Jul;216(1):44-54. doi: 10.1097/00000658-199207000-00007. PMID: 1632701; PMCID: PMC1242545.
- Oba K, Teramukai S, Kobayashi M, Matsui T, Kodera Y, Sakamoto J. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer. Cancer Immunol Immunother. 2007 Jun;56(6):905-11. doi: 10.1007/s00262-006-0248-1. Epub 2006 Nov 15. PMID: 17106715; PMCID: PMC11030720.
- Nakazato H, Koike A, Saji S, Ogawa N, Sakamoto J. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer. Lancet. 1994 May 7;343(8906):1122-6. doi: 10.1016/s0140-6736(94)90233-x. PMID: 7910230.
- Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer, Nakazato, Hiroaki et al., The Lancet, Volume 343, Issue 8906, 1122 - 1126
- Hsu JT, Hsu CS, Le PH, Chen TC, Chou WC, Lin CY, Yeh TS. Immunochemotherapy benefits in gastric cancer patients stratified by programmed death-1 ligand-1. J Surg Res. 2017 May 1;211:30-38. doi: 10.1016/j.jss.2016.11.058. Epub 2016 Dec 11. PMID: 28501128.
- Fukuchi M, Mochiki E, Ishiguro T, Ogura T, Sobajima J, Kumagai Y, Ishibashi K, Ishida H. Improved Efficacy by Addition of Protein-bound Polysaccharide K to Adjuvant Chemotherapy for Advanced Gastric Cancer. Anticancer Res. 2016 Aug;36(8):4237-41. PMID: 27466538.
- Yoshikawa K, Shimada M, Kurita N, Sato H, Iwata T, Nishioka M, Morimoto S, Miyatani T, Komatsu M, And RN. The effect of polysaccharide k with S-1 based chemotherapy in advanced gastric cancer. Hepatogastroenterology. 2013 Sep;60(126):1387-90. doi: 10.5754/hge11355. PMID: 23933930.
- Maehara Y, Tsujitani S, Saeki H, Oki E, Yoshinaga K, Emi Y, Morita M, Kohnoe S, Kakeji Y, Yano T, Baba H. Biological mechanism and clinical effect of protein-bound polysaccharide K (KRESTIN(®)): review of development and future perspectives. Surg Today. 2012 Jan;42(1):8-28. doi: 10.1007/s00595-011-0075-7. Epub 2011 Dec 6. PMID: 22139128; PMCID: PMC3253283.
- Ito G, Tanaka H, Ohira M, Yoshii M, Muguruma K, Kubo N, Yashiro M, Yamada N, Maeda K, Sawada T, Hirakawa K. Correlation between efficacy of PSK postoperative adjuvant immunochemotherapy for gastric cancer and expression of MHC class I. Exp Ther Med. 2012 Jun;3(6):925-930. doi: 10.3892/etm.2012.537. Epub 2012 Apr 2. PMID: 22969994; PMCID: PMC3438816.
- Wang TY, Chen CY, Huang TH, Yang YH, Chen KJ, Chou WC, Lu CH. Protein-bound polysaccharide K prolonged overall survival in gastric cancer patients from a non-Japanese Asian country who received gastrectomy and adjuvant chemotherapy. Medicine (Baltimore). 2022 Jul 22;101(29):e29632. doi: 10.1097/MD.0000000000029632. PMID: 35866836; PMCID: PMC9302315.
- A comprehensive multi-institutional study on postoperative adjuvant immunotherapy with oral streptococcal preparation OK-432 for patients after gastric cancer surgery. Kyoto Research Group for Digestive Organ Surgery. Ann Surg. 1992 Jul;216(1):44-54. doi: 10.1097/00000658-199207000-00007. PMID: 1632701; PMCID: PMC1242545.
- Kondo T, Sakamoto J, Nakazato H. Alternating immunochemotherapy of advanced gastric carcinoma: a randomized comparison of carbazilquinone and PSK to carbazilquinone in patients with curative gastric resection. Biotherapy. 1991;3(4):287-95. doi: 10.1007/BF02221321. PMID: 1786194.